Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Idorsia's Enterprise Value is CHF2,797.2 Mil.
Idorsia's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-119.2 Mil. Therefore, Idorsia's EV-to-OCF for today is -23.47.
The historical rank and industry rank for Idorsia's EV-to-OCF or its related term are showing as below:
XSWX:IDIA'
s EV-to-OCF Range Over the Past 10 Years
Min: -65.55 Med: -5.68 Max: 32.57
Current: -23.76
During the past 10 years, the highest EV-to-OCF of Idorsia was 32.57. The lowest was -65.55. And the median was -5.68.
XSWX:IDIA's EV-to-OCF is ranked better than 83.83% of 1410
companies
in the Biotechnology industry
Industry Median: -3.315
vs XSWX:IDIA: -23.76
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-25), Idorsia's stock price is CHF6.165.
Idorsia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-1.030. Therefore, Idorsia's PE Ratio (TTM) for today is At Loss.
Idorsia (XSWX:IDIA) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Idorsia's share price for today is CHF6.165.
Idorsia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-1.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Idorsia EV-to-OCF Related Terms
Idorsia EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Idorsia's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:IDIA vs VRTX, REGN, ALNY: EV-to-OCF Comparison
For the Biotechnology subindustry, Idorsia's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Idorsia EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Idorsia's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Idorsia's EV-to-OCF falls into.
Idorsia's current Enterprise Value is CHF2,797.2 Mil.
Idorsia's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-119.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Idorsia (XSWX:IDIA) has a EV-to-OCF of -23.47 as of Jul. 25, 2026. According to the industry distribution chart, Idorsia ranks #228 out of 1410 companies in the Biotechnology industry, placing it in the top 16.2%.
Is Idorsia's EV-to-OCF too high?
Idorsia's current EV-to-OCF is -23.47. Based on the distribution chart, Idorsia ranks #228 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Idorsia has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Idorsia ranks #228 out of 1410 companies for EV-to-OCF. This places Idorsia in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Idorsia's current EV-to-OCF is -23.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (XSWX:IDIA) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.90, compared to a current price of CHF6.17 — trading 112.6% above its estimated fair value. The current EV-to-OCF is -23.47. Idorsia's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Idorsia (XSWX:IDIA), the current EV-to-OCF is -23.47 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Idorsia (XSWX:IDIA) Overvalued in 2026?
Based on GuruFocus' analysis, Idorsia stock appears to be overvalued.
The current stock price of CHF6.17 is trading 112.6% above its estimated GF Value™ of CHF2.90.
GuruFocus considers Idorsia to be Significantly Overvalued.
Key valuation signals for XSWX:IDIA:
EV-to-OCF: -23.47
GF Value™: CHF2.90 vs. price of CHF6.17 (112.6% above fair value)
No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
48GF Score
Get the complete analysis for XSWX:IDIA
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:IDIA has been successfully added to your 
